AU2020232314C1 - Pharmaceutical compositions for treating ocular diseases or disorders - Google Patents

Pharmaceutical compositions for treating ocular diseases or disorders Download PDF

Info

Publication number
AU2020232314C1
AU2020232314C1 AU2020232314A AU2020232314A AU2020232314C1 AU 2020232314 C1 AU2020232314 C1 AU 2020232314C1 AU 2020232314 A AU2020232314 A AU 2020232314A AU 2020232314 A AU2020232314 A AU 2020232314A AU 2020232314 C1 AU2020232314 C1 AU 2020232314C1
Authority
AU
Australia
Prior art keywords
biodegradable
pharmaceutical composition
weight
lactide
polymer matrix
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2020232314A
Other languages
English (en)
Other versions
AU2020232314B2 (en
AU2020232314A1 (en
Inventor
Sanjib Kumar Das
Cheng-Wen Lin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alcon Inc
Original Assignee
Alcon Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alcon Inc filed Critical Alcon Inc
Publication of AU2020232314A1 publication Critical patent/AU2020232314A1/en
Publication of AU2020232314B2 publication Critical patent/AU2020232314B2/en
Application granted granted Critical
Publication of AU2020232314C1 publication Critical patent/AU2020232314C1/en
Assigned to ALCON INC. reassignment ALCON INC. Request for Assignment Assignors: AERIE PHARMACEUTICALS, INC.
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts or implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Materials For Medical Uses (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Biological Depolymerization Polymers (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Polyamides (AREA)
AU2020232314A 2019-03-05 2020-03-05 Pharmaceutical compositions for treating ocular diseases or disorders Active AU2020232314C1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962814198P 2019-03-05 2019-03-05
US62/814,198 2019-03-05
PCT/US2020/021136 WO2020181060A1 (en) 2019-03-05 2020-03-05 Pharmaceutical compositions for treating ocular diseases or disorders

Publications (3)

Publication Number Publication Date
AU2020232314A1 AU2020232314A1 (en) 2021-09-30
AU2020232314B2 AU2020232314B2 (en) 2023-10-12
AU2020232314C1 true AU2020232314C1 (en) 2024-03-28

Family

ID=72337143

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2020232314A Active AU2020232314C1 (en) 2019-03-05 2020-03-05 Pharmaceutical compositions for treating ocular diseases or disorders

Country Status (10)

Country Link
US (2) US12478577B2 (https=)
EP (1) EP3934646A4 (https=)
JP (3) JP7570342B2 (https=)
KR (1) KR20210135560A (https=)
CN (3) CN118304422A (https=)
AU (1) AU2020232314C1 (https=)
BR (1) BR112021017436A2 (https=)
CA (1) CA3132635A1 (https=)
MX (2) MX2021010599A (https=)
WO (1) WO2020181060A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20210135560A (ko) 2019-03-05 2021-11-15 에어리 파마슈티컬즈, 인코포레이티드 안구 질환 또는 장애를 치료하는 약학 조성물
PT3861985T (pt) 2020-02-06 2023-08-03 Ocular Therapeutix Inc Composições e métodos para tratar doenças oculares
PT3884929T (pt) 2020-03-25 2023-08-09 Ocular Therapeutix Inc Implante ocular contendo um inibidor da tirosina cinase
US20230149387A1 (en) * 2020-04-08 2023-05-18 Aerie Pharmaceuticals, Inc. Treatments
EP4329753A4 (en) 2021-04-30 2025-02-26 Perfuse Therapeutics, Inc. PHARMACEUTICAL COMPOSITIONS AND INTRAVITREAL DRUG DELIVERY SYSTEMS FOR THE TREATMENT OF EYE DISEASES
US20240239750A1 (en) 2021-05-05 2024-07-18 Aerie Pharmaceuticals, Inc. Pharmaceutical preparation
PE20260040A1 (es) 2023-04-11 2026-01-09 Ocular Therapeutix Inc Implante ocular que contiene un inhibidor de la tirosina cinasa
WO2025146683A1 (en) 2024-01-03 2025-07-10 Lyotropic Delivery Systems Ltd. Topical formulations for delivery of an active compound to the back of the eye
WO2025169089A1 (en) 2024-02-05 2025-08-14 Sun Pharmaceutical Industries Limited Ophthalmic compositions of tyrosine kinase inhibitors and their uses

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2704748A1 (en) * 2011-05-02 2014-03-12 DSM IP Assets B.V. Bis-(alpha-amino-diol-diester) containing polyesteramide for ophtamology
US9798189B2 (en) * 2010-06-22 2017-10-24 Toyobo Co., Ltd. Liquid crystal display device, polarizer and protective film
EP3233067A1 (en) * 2014-12-18 2017-10-25 DSM IP Assets B.V. Drug delivery system for delivery of acid sensitive drugs

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2649672C (en) * 2006-05-02 2015-07-07 Medivas, Llc Delivery of ophthalmologic agents to the exterior or interior of the eye
US20110158910A1 (en) 2008-04-25 2011-06-30 Aylvin Jorge Angelo Athanasius Dias Microparticles comprising polymers with thioester bonds
US9095506B2 (en) 2008-11-17 2015-08-04 Allergan, Inc. Biodegradable alpha-2 agonist polymeric implants and therapeutic uses thereof
BR112013018739A2 (pt) * 2010-12-29 2019-09-24 Jade Therapeutics Inc sistema de distribuição de medicamento ocular
JP6135870B2 (ja) * 2011-05-02 2017-05-31 ディーエスエム アイピー アセッツ ビー．ブイ． 生分解性ポリマーを含む繊維
WO2013126799A1 (en) * 2012-02-22 2013-08-29 Trustees Of Tufts College Compositions and methods for ocular delivery of a therapeutic agent
CN104717962B (zh) * 2012-10-02 2017-07-21 帝斯曼知识产权资产管理有限公司 包含蛋白质和可生物降解聚酯酰胺的药物递送组合物
EP3702394B1 (en) 2012-10-24 2023-11-22 DSM IP Assets B.V. Fibers comprising polyesteramide copolymers for drug delivery
EP2956096A1 (en) * 2013-02-15 2015-12-23 Allergan, Inc. Sustained drug delivery implant
AU2014248460B2 (en) 2013-04-01 2019-04-11 Allergan, Inc. Microsphere drug delivery system for sustained intraocular release
WO2015126477A1 (en) 2013-11-08 2015-08-27 Tyrx, Inc. Polymeric drug delivery system for treating surgical complications
US20160296627A1 (en) * 2013-12-06 2016-10-13 Envisia Therapeutics Inc. Intracameral implant for treatment of an ocular condition
CA2933900A1 (en) 2013-12-20 2015-06-25 Georgia Tech Research Corporation Formulations and methods for targeted ocular delivery of therapeutic agents
US9931306B2 (en) 2014-09-06 2018-04-03 Integral Biosystems Llc Methods and biocompatible compositions to achieve sustained drug release in the eye
CN108883070A (zh) 2015-07-23 2018-11-23 爱瑞制药公司 用于治疗眼病的玻璃体内药物递送系统
WO2017120600A1 (en) 2016-01-08 2017-07-13 Clearside Biomedical, Inc. Compositions and methods of treating wet age-related macular degeneration
US20180117148A1 (en) * 2016-10-28 2018-05-03 Andrew J. Holman Compounds, pharmaceutical compositions and methods of treatments of immune related diseases and disorders
AU2018226872A1 (en) 2017-03-03 2019-09-05 Macregen, Inc. Treatment of age-related macular degeneration and other eye diseases with one or more therapeutic agents
KR20210135560A (ko) 2019-03-05 2021-11-15 에어리 파마슈티컬즈, 인코포레이티드 안구 질환 또는 장애를 치료하는 약학 조성물

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9798189B2 (en) * 2010-06-22 2017-10-24 Toyobo Co., Ltd. Liquid crystal display device, polarizer and protective film
EP2704748A1 (en) * 2011-05-02 2014-03-12 DSM IP Assets B.V. Bis-(alpha-amino-diol-diester) containing polyesteramide for ophtamology
EP3233067A1 (en) * 2014-12-18 2017-10-25 DSM IP Assets B.V. Drug delivery system for delivery of acid sensitive drugs

Also Published As

Publication number Publication date
KR20210135560A (ko) 2021-11-15
US12478577B2 (en) 2025-11-25
US20260034056A1 (en) 2026-02-05
CN118286445A (zh) 2024-07-05
JP7852008B2 (ja) 2026-04-27
US20200306182A1 (en) 2020-10-01
JP7570342B2 (ja) 2024-10-21
CN118304422A (zh) 2024-07-09
MX2021010599A (es) 2021-12-10
EP3934646A1 (en) 2022-01-12
JP2022523548A (ja) 2022-04-25
WO2020181060A1 (en) 2020-09-10
BR112021017436A2 (pt) 2021-11-16
CN113784727B (zh) 2024-03-29
CA3132635A1 (en) 2020-09-10
JP2025004161A (ja) 2025-01-14
AU2020232314B2 (en) 2023-10-12
JP7838047B2 (ja) 2026-03-31
JP2025004160A (ja) 2025-01-14
MX2025002265A (es) 2025-04-02
AU2020232314A1 (en) 2021-09-30
EP3934646A4 (en) 2022-12-14
CN113784727A (zh) 2021-12-10

Similar Documents

Publication Publication Date Title
AU2020232314C1 (en) Pharmaceutical compositions for treating ocular diseases or disorders
US11116776B2 (en) Intravitreal drug delivery systems for the treatment of ocular conditions
JP5608138B2 (ja) 生分解性チロシンキナーゼインヒビター硝子体内インプラント
JP6570513B2 (ja) 持続的眼内放出のためのマイクロスフェア薬剤送達システム
TWI501766B (zh) 製造生物可分解之玻璃體內酪胺酸激酶之植入物的方法
JP6546194B2 (ja) 眼性状態を処置するための前房内インプラント
JP2016513109A (ja) 持続型薬物送達インプラント
JP2007535367A (ja) エストラジオール誘導体またはエストラトポン誘導体を含有する徐放性眼内インプラント、ならびに関連する製造法
AU2016269432A1 (en) Biodegradable introcular tyrosine kinase inhibitor implants
JP2023500035A (ja) 高いガラス転移温度を有するポリエステルアミドコポリマー

Legal Events

Date Code Title Description
DA2 Applications for amendment section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 14 DEC 2023

DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 14 DEC 2023

FGA Letters patent sealed or granted (standard patent)
PC Assignment registered

Owner name: ALCON INC.

Free format text: FORMER OWNER(S): AERIE PHARMACEUTICALS, INC.